Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 90 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 60 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 45 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 30 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 15 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - tablet - 50 mg - nefazodone hydrochloride tablets, usp is indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, usp treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - the treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. the treatment of adults with gastrointestional infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - volibris is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), -pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms. volibris in combination with tadalafil is indicated for the treatment of who group 1 pulmonary arterial hypertension in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - volibris is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), -pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms. volibris in combination with tadalafil is indicated for the treatment of who group 1 pulmonary arterial hypertension in patients with who functional class ii, iii or iv symptoms.